Rilonacept (Interleukin-1 Trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: Results of a phase II randomized, double-blind, placebo-controlled trial

Objective To evaluate the interleukin‐1 inhibitor rilonacept (Interleukin‐1 Trap) for prevention of gout flares occurring in the first few months following initiation of urate‐lowering therapy. Methods In this double‐blind study, adult patients with hyperuricemia and gout were randomized to receive...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2012-03, Vol.64 (3), p.876-884
Hauptverfasser:	Schumacher Jr, H. Ralph, Sundy, John S., Terkeltaub, Robert, Knapp, Howard R., Mellis, Scott J., Stahl, Neil, Yancopoulos, George D., Soo, Yuhwen, King-Davis, Shirletta, Weinstein, Steven P., Radin, Allen R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Allopurinol - therapeutic use Biological and medical sciences Cytokines Diseases of the osteoarticular system Double-Blind Method Drug therapy Female Gout - drug therapy Gout - pathology Gout Suppressants - therapeutic use Humans Hyperuricemia - drug therapy Hyperuricemia - pathology Inflammatory joint diseases Injections, Subcutaneous Male Medical research Medical sciences Metabolic diseases Middle Aged Miscellaneous. Osteoarticular involvement in other diseases Other metabolic disorders Purines and pyrimidines (gout, hyperuricemia...) Recombinant Fusion Proteins - administration & dosage Recombinant Fusion Proteins - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!